CCL11 (eotaxin-1) is a CC-motif chemokine that serves as a potent chemoattractant for eosinophils, basophils, macrophages, and dendritic cells, primarily through binding to the CCR3 receptor 12. Beyond leukocyte recruitment, CCL11 promotes endothelial cell chemotaxis and angiogenesis via PI3K/Akt pathway activation 3. CCL11 plays central roles in allergic inflammation and asthma pathogenesis 4, where it mediates eosinophil recruitment to lung tissues. Recent evidence reveals broader pathological implications: CCL11 induces cellular senescence in lung fibroblasts through reactive oxygen species production and DNA damage response activation 5, with elevated plasma levels associated with neuroinflammatory disorders and COVID-19 neurologic complications 6. Elevated serum CCL11 correlates with diabetic sensorimotor polyneuropathy severity and peripheral nerve dysfunction 7. In psychiatric disorders, CCL11 levels are significantly elevated in schizophrenia and bipolar disorder patients, correlating with hospitalization frequency 8. Notably, in pancreatic cancer, ATX-mediated suppression of CCL11 expression promotes tumor progression by reducing eosinophil infiltration 9. CCL11 polymorphisms show associations with atopic dermatitis risk 10. Collectively, CCL11 functions as both an acute inflammatory mediator and a biomarker for chr17 age-related and neuroinflammatory pathologies.